AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22496116 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=103)
Number of subjects: 204
Study 20546443 — intervention group
Group type: EXPERIMENTAL
Intervention: EGD-colonoscopy (Group I)
Number of subjects: 80
Study 20546443 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy-EGD (Group II)
Number of subjects: 80
Study 18573001 — intervention group
Group type: EXPERIMENTAL
Intervention: Source recall tests
Number of subjects: 0
Study 18573001 — intervention group
Group type: COMPARATOR
Intervention: Free recall tests
Number of subjects: 0
Study 16642482 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported goiter
Number of subjects: 29584
Study 12942685 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal sampling design (D-optimal design)
Number of subjects: 96
Study 12942685 — intervention group
Group type: COMPARATOR
Intervention: Empirical sampling design
Number of subjects: 96
Study 11340885 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical pachometry
Number of subjects: 50
Study 11340885 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound pachometry
Number of subjects: 50
Study 8977608 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 17
Study 8977608 — intervention group
Group type: COMPARATOR
Intervention: Intravenous doxapram
Number of subjects: 17
Study 1731594 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment (prednisolone) for 8 weeks
Number of subjects: 36
Study 1731594 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 8 weeks
Number of subjects: 36
Study 6609598 — intervention group
Group type: EXPERIMENTAL
Intervention: Golytely alone
Number of subjects: 200
Study 6609598 — intervention group
Group type: EXPERIMENTAL
Intervention: Golytely plus Dulcolax (bisacodyl)
Number of subjects: 200
Study 6609598 — intervention group
Group type: COMPARATOR
Intervention: Standard diet/cathartic preparation
Number of subjects: 200
Study 30091172 — intervention group
Group type: EXPERIMENTAL
Intervention: Empa/Lina 10/5
Number of subjects: 223
Study 30091172 — intervention group
Group type: COMPARATOR
Intervention: Empa/Plc 10/5
Number of subjects: 223
Study 30091172 — intervention group
Group type: EXPERIMENTAL
Intervention: Empa/Lina 25/5
Number of subjects: 223
Study 30091172 — intervention group
Group type: COMPARATOR
Intervention: Empa/Plc 25/5
Number of subjects: 223
Study 30091172 — intervention group
Group type: EXPERIMENTAL
Intervention: Empa/Lina
Number of subjects: 223
Study 28112426 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 400 mg, three times daily for 2 weeks
Number of subjects: 86
Study 28112426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 25562853 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer intervention encouraging 10,000 steps/day
Number of subjects: 0
Study 23743811 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic resveratrol supplementation (75 mg daily for 6 weeks)
Number of subjects: 28
Study 23743811 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of resveratrol (75 mg) after chronic supplementation
Number of subjects: 28
Study 23743811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 21514710 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal dexamethasone
Number of subjects: 33
Study 21514710 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular dexamethasone
Number of subjects: 33
Study 21514710 — intervention group
Group type: COMPARATOR
Intervention: Control group (no steroid)
Number of subjects: 33
Study 18812241 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progesterone
Number of subjects: 33
Study 18812241 — intervention group
Group type: COMPARATOR
Intervention: Estrogen
Number of subjects: 33
Study 18812241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 16508131 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate treatment
Number of subjects: 0
Study 14511272 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined manipulative therapy and therapeutic exercise
Number of subjects: 200
Study 14511272 — intervention group
Group type: COMPARATOR
Intervention: Manipulative therapy
Number of subjects: 200
Study 14511272 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 200
Study 11144946 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane stents (10 French diameter)
Number of subjects: 38
Study 11144946 — intervention group
Group type: COMPARATOR
Intervention: Standard plastic stents (10 French diameter)
Number of subjects: 38
Study 11144946 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (polyurethane and standard plastic stents)
Number of subjects: 38
Study 8740309 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone treatment
Number of subjects: 7
Study 8740309 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 7
Study 1421932 — intervention group
Group type: EXPERIMENTAL
Intervention: traditional rice‐lentil (Khitchri) diet and yogurt (K‐Y)
Number of subjects: 102
Study 1421932 — intervention group
Group type: EXPERIMENTAL
Intervention: soy formula (alone for seven days and then in combination with K‐Y for seven days)
Number of subjects: 102
Study 6420832 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorimipramine (CI) 25 mg
Number of subjects: 12
Study 6420832 — intervention group
Group type: EXPERIMENTAL
Intervention: Desimipramine (DMI) 25 mg
Number of subjects: 12
Study 28224644 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone injection (ITDI)
Number of subjects: 54
Study 28224644 — intervention group
Group type: COMPARATOR
Intervention: Intratympanic normal saline injection (ITNI)
Number of subjects: 54
Study 26626581 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD4901 40 mg twice daily (BID)
Number of subjects: 0
Study 26626581 — intervention group
Group type: COMPARATOR
Intervention: AZD4901 80 mg once daily (QD)
Number of subjects: 0
Study 25652842 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap-assisted colonoscopy
Number of subjects: 427
Study 25652842 — intervention group
Group type: COMPARATOR
Intervention: Standard high-definition white light colonoscopy
Number of subjects: 427
Study 23977910 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg intravenous dexamethasone
Number of subjects: 10
Study 23977910 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 10
Study 20360317 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (10-40 mg/day)
Number of subjects: 81
Study 20360317 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (300-1200 mg/day)
Number of subjects: 81
Study 20360317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 18484901 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day) for 8 weeks
Number of subjects: 50
Study 18484901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 17029334 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of oral pravastatin once daily for up to 14 days
Number of subjects: 80
Study 17029334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 12194927 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin (0.5 microg/kg of body weight)
Number of subjects: 40
Study 12194927 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (20 mg twice a day for 4 days)
Number of subjects: 40
Study 10604689 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin 500 mg twice daily for 1 month
Number of subjects: 30
Study 10604689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10604689 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosta-Q (quercetin, bromelain, and papain) in an open-label study
Number of subjects: 30
Study 7577278 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 2 mg (group B)
Number of subjects: 0
Study 7577278 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% Mepivacaine alone (group M)
Number of subjects: 0
Study 7577278 — intervention group
Group type: COMPARATOR
Intervention: 0.5% Mepivacaine-Butorphanol (group MB)
Number of subjects: 0
Study 1686130 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antipruritic corticosteroid
Number of subjects: 30
Study 1686130 — intervention group
Group type: COMPARATOR
Intervention: Clemastine (sedative antihistamine)
Number of subjects: 30
Study 1686130 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine (non-sedative antihistamine)
Number of subjects: 30
Study 1686130 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CSA)
Number of subjects: 30
Study 7198413 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane 3%
Number of subjects: 90
Study 7198413 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.02 mg/kg followed by halothane 3%
Number of subjects: 90
Study 7198413 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane 1.25% followed by succinylcholine 2 mg/kg
Number of subjects: 90
Study 31985516 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (6 cycles)
Number of subjects: 163
Study 31985516 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine + Erlotinib (100 mg/d)
Number of subjects: 163
Study 31985516 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 163
Study 31985516 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine + Erlotinib
Number of subjects: 163
Study 30409759 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative Flow Ratio (QFR)
Number of subjects: 138
Study 30409759 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional SYNTAX score derived from QFR (fSSQFR)
Number of subjects: 138
Study 30409759 — intervention group
Group type: COMPARATOR
Intervention: Classic anatomic SYNTAX score
Number of subjects: 138
Study 29166256 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 0
Study 29166256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26743136 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest 2 mg/die for 5 weeks
Number of subjects: 80
Study 26743136 — intervention group
Group type: COMPARATOR
Intervention: Danazol 100 mg/die for 5 weeks
Number of subjects: 80
Study 25246692 — intervention group
Group type: EXPERIMENTAL
Intervention: Arachidonic acid (10 mg/kg per day for 15 days)
Number of subjects: 66
Study 25246692 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (40 mg/kg single dose)
Number of subjects: 66
Study 25246692 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (40 mg/kg single dose) combined with Arachidonic acid (10 mg/kg per day for 15 days)
Number of subjects: 66
Study 22759333 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole with amoxicillin and clarithromycin (LAC)
Number of subjects: 222
Study 22759333 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily dosage of PPI and clarithromycin
Number of subjects: 222
Study 22759333 — intervention group
Group type: EXPERIMENTAL
Intervention: Exact antibiotic dose per body weight
Number of subjects: 222
Study 22759333 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily PPI versus once daily for LAM regimen
Number of subjects: 222
Study 19171708 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg twice daily
Number of subjects: 189
Study 19171708 — intervention group
Group type: COMPARATOR
Intervention: IFN-alpha-2a 9 million U three times weekly
Number of subjects: 189
Study 19171708 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 600 mg twice daily (after progression)
Number of subjects: 189
Study 19171708 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg twice daily (after switch from IFN-alpha-2a)
Number of subjects: 189
Study 19171708 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 189
Study 19171708 — intervention group
Group type: COMPARATOR
Intervention: IFN-alpha-2a
Number of subjects: 189
Study 17593840 — intervention group
Group type: EXPERIMENTAL
Intervention: Eco-nutrition enteral nutrition (EEN)
Number of subjects: 32
Study 15543326 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) treatment prior to elective surgery
Number of subjects: 71
Study 15543326 — intervention group
Group type: COMPARATOR
Intervention: Untreated AAA patients (control group)
Number of subjects: 71
Study 12393357 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (continuous i.v. infusion starting at 0.025 micro g kg(‐1) min(‐1))
Number of subjects: 60
Study 12393357 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil (i.v. doses of 0.15 micro g kg(‐1))
Number of subjects: 60
Study 9952092 — intervention group
Group type: EXPERIMENTAL
Intervention: SGB (6 mL 1% lidocaine at C6)
Number of subjects: 24
Study 9952092 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (6 mL 1% lidocaine injected into subcutaneous tissue)
Number of subjects: 24
Study 9952092 — intervention group
Group type: COMPARATOR
Intervention: Saline (6 mL saline solution at C6)
Number of subjects: 24
Study 7490909 — intervention group
Group type: COMPARATOR
Intervention: Iron supplementation for 8 weeks
Number of subjects: 371
Study 7490909 — intervention group
Group type: COMPARATOR
Intervention: Iron treatment for 4 months
Number of subjects: 371
Study 7490909 — intervention group
Group type: EXPERIMENTAL
Intervention: Training course for mothers on rearing environment for 21 days
Number of subjects: 371
Study 2253528 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg intravenous bolus dose of edrophonium
Number of subjects: 150
Study 2253528 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 micrograms/kg intravenous bolus dose of edrophonium
Number of subjects: 150
Study 2253528 — intervention group
Group type: COMPARATOR
Intervention: saline placebo injections
Number of subjects: 150
Study 7406571 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg every six hours)
Number of subjects: 144
Study 7406571 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (maximum dose)
Number of subjects: 144
Study 7406571 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacids (average requirement 41 cc/hour)
Number of subjects: 144
Study 7406571 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (initial treatment)
Number of subjects: 144
Study 7406571 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacids (supplementary dose)
Number of subjects: 144
Study 7406571 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (cimetidine and antacids)
Number of subjects: 144
Study 30411598 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue flossing intervention on one arm
Number of subjects: 17
Study 30411598 — intervention group
Group type: COMPARATOR
Intervention: Control (non-flossed arm)
Number of subjects: 17
Study 30411598 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue flossing intervention
Number of subjects: 17
Study 27920018 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1,200 mg single dose
Number of subjects: 100
Study 27920018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 27920018 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1,200 mg single dose (open-label post-trial study)
Number of subjects: 100
Study 25697217 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) + oxaliplatin
Number of subjects: 32745
Study 25697217 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 32745
Study 25697217 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)
Number of subjects: 32745
Study 25697217 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence-free patients
Number of subjects: 32745
Study 25697217 — intervention group
Group type: COMPARATOR
Intervention: Overall CC patients
Number of subjects: 32745
Study 23703408 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal balloon treatment with a Fogarty balloon catheter (n = 32)
Number of subjects: 62
Study 23703408 — intervention group
Group type: COMPARATOR
Intervention: Control group (transforaminal steroid injection without balloon treatment, n = 30)
Number of subjects: 62
Study 19346411 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (fresh produce only)
Number of subjects: 21
Study 19346411 — intervention group
Group type: COMPARATOR
Intervention: Control group (any groceries)
Number of subjects: 21
Study 19125992 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 12.5 mg
Number of subjects: 527
Study 19125992 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg
Number of subjects: 527
Study 19125992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 527
Study 17431496 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental amalgam restorations
Number of subjects: 534
Study 17431496 — intervention group
Group type: COMPARATOR
Intervention: Mercury-free composite materials
Number of subjects: 534
Study 14768776 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestige IQ blood glucose monitoring device
Number of subjects: 61
Study 14768776 — intervention group
Group type: COMPARATOR
Intervention: Other four commercially available blood glucose devices
Number of subjects: 61
Study 11029841 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive
Number of subjects: 200
Study 11029841 — intervention group
Group type: COMPARATOR
Intervention: Control (no financial incentive)
Number of subjects: 200
Study 8787880 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g every 8 h (q8h) bolus dosing (BD)
Number of subjects: 12
Study 8787880 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g every 12 h (q12h) bolus dosing (BD)
Number of subjects: 12
Study 8787880 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g over 24 h continuous infusion (CI)
Number of subjects: 12
Study 8787880 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g over 24 h continuous infusion (CI)
Number of subjects: 12
Study 8787880 — intervention group
Group type: COMPARATOR
Intervention: Intermittent dosing (BD)
Number of subjects: 12
Study 1465079 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein restriction diet
Number of subjects: 456
Study 1465079 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrosclerosis
Number of subjects: 456
Study 1465079 — intervention group
Group type: EXPERIMENTAL
Intervention: Interstitial nephropathy
Number of subjects: 456
Study 1465079 — intervention group
Group type: EXPERIMENTAL
Intervention: Glomerulonephritis
Number of subjects: 456
Study 1465079 — intervention group
Group type: EXPERIMENTAL
Intervention: Polycystic kidney disease
Number of subjects: 456
Study 6370151 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual penicillamine withdrawal
Number of subjects: 38
Study 6370151 — intervention group
Group type: EXPERIMENTAL
Intervention: Reintroduction of penicillamine
Number of subjects: 38
Study 6370151 — intervention group
Group type: EXPERIMENTAL
Intervention: Serological marker for predicting relapse
Number of subjects: 38
Study 6370151 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing SH levels
Number of subjects: 38
Study 3537288 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethicone-containing antacid gel (Asilone Gel)
Number of subjects: 45
Study 3537288 — intervention group
Group type: COMPARATOR
Intervention: Simple antacid gel
Number of subjects: 45
Study 29417463 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dose combination tablet of sofosbuvir and ledipasvir (400/90 mg)
Number of subjects: 36
Study 29417463 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro dissolution study
Number of subjects: 36
Study 26654958 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathic patient-centered approach (IG)
Number of subjects: 104
Study 26654958 — intervention group
Group type: COMPARATOR
Intervention: Standardized information on surgical procedures (CG)
Number of subjects: 104
Study 25583761 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with the everolimus-eluting stent
Number of subjects: 0
Study 25583761 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass graft (CABG) surgery
Number of subjects: 0
Study 24314158 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Number of subjects: 100
Study 24314158 — intervention group
Group type: COMPARATOR
Intervention: Enteral Nutrition (EN)
Number of subjects: 100
Study 21271020 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification (PHACO)
Number of subjects: 205
Study 21271020 — intervention group
Group type: COMPARATOR
Intervention: Extracapsular extraction (EECP)
Number of subjects: 205
Study 18649055 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 48
Study 18649055 — intervention group
Group type: COMPARATOR
Intervention: Control group (no atorvastatin)
Number of subjects: 48
Study 16628033 — intervention group
Group type: COMPARATOR
Intervention: Group A (2.0 mL/kg of 300 mgI/mL contrast medium, injection duration 30 seconds, mean rate 3.6 mL/sec)
Number of subjects: 60
Study 16628033 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (2.0 mL/kg of 300 mgI/mL contrast medium, injection duration 25 seconds, mean rate 4.6 mL/sec)
Number of subjects: 60
Study 16628033 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (2.0 mL/kg of 300 mgI/mL contrast medium, injection duration 30 seconds, mean rate 3.6 mL/sec followed by saline chaser)
Number of subjects: 60
Study 14634681 — intervention group
Group type: EXPERIMENTAL
Intervention: Skill-based intervention (SBI)
Number of subjects: 80
Study 14634681 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling-based intervention (CBI)
Number of subjects: 80
Study 10825333 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.4 mg/kg IV before skin incision
Number of subjects: 89
Study 10825333 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.04 mL/kg IV immediately before and after surgery (Placebo)
Number of subjects: 89
Study 10825333 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline before skin incision, Ketamine 0.4 mg/kg IV after skin closure
Number of subjects: 89
Study 8865508 — intervention group
Group type: EXPERIMENTAL
Intervention: Manually adjusted CPAP
Number of subjects: 20
Study 8865508 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-titrating CPAP
Number of subjects: 20